BR112021026408A2 - Receptores de célula t que reconhecem a mutação r175h ou y220c em p53 - Google Patents

Receptores de célula t que reconhecem a mutação r175h ou y220c em p53

Info

Publication number
BR112021026408A2
BR112021026408A2 BR112021026408A BR112021026408A BR112021026408A2 BR 112021026408 A2 BR112021026408 A2 BR 112021026408A2 BR 112021026408 A BR112021026408 A BR 112021026408A BR 112021026408 A BR112021026408 A BR 112021026408A BR 112021026408 A2 BR112021026408 A2 BR 112021026408A2
Authority
BR
Brazil
Prior art keywords
cell receptors
mutation
recognize
present
mammal
Prior art date
Application number
BR112021026408A
Other languages
English (en)
Portuguese (pt)
Inventor
Anna Pasetto
C Deniger Drew
Parisa Malekzadeh
A Rosenberg Steven
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of BR112021026408A2 publication Critical patent/BR112021026408A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4748—Details p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Oncology (AREA)
BR112021026408A 2019-06-27 2020-06-26 Receptores de célula t que reconhecem a mutação r175h ou y220c em p53 BR112021026408A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962867619P 2019-06-27 2019-06-27
PCT/US2020/039785 WO2020264269A1 (en) 2019-06-27 2020-06-26 T cell receptors recognizing r175h or y220c mutation in p53

Publications (1)

Publication Number Publication Date
BR112021026408A2 true BR112021026408A2 (pt) 2022-02-08

Family

ID=71662353

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021026408A BR112021026408A2 (pt) 2019-06-27 2020-06-26 Receptores de célula t que reconhecem a mutação r175h ou y220c em p53

Country Status (11)

Country Link
US (1) US12479902B2 (cg-RX-API-DMAC7.html)
EP (1) EP3990481A1 (cg-RX-API-DMAC7.html)
JP (2) JP7635165B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220047969A (cg-RX-API-DMAC7.html)
CN (1) CN114341171A (cg-RX-API-DMAC7.html)
AU (1) AU2020308004B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021026408A2 (cg-RX-API-DMAC7.html)
CA (1) CA3144070A1 (cg-RX-API-DMAC7.html)
MX (2) MX2021015877A (cg-RX-API-DMAC7.html)
TW (2) TW202525841A (cg-RX-API-DMAC7.html)
WO (1) WO2020264269A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019077062A1 (en) * 2017-10-18 2019-04-25 Vivia Biotech, S.L. C-CELLS ACTIVATED BY BIT
JP2024507929A (ja) 2021-02-25 2024-02-21 アラウノス セラピューティクス インコーポレイテッド 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法
WO2022232599A1 (en) * 2021-04-30 2022-11-03 Regents Of The University Of Minnesota Mesothelin-specific t cell receptors and methods of using same
AU2022271195A1 (en) * 2021-05-03 2023-11-02 Bluesphere Bio, Inc. T cell receptors (tcrs) targeting minor histocompatibility antigen ha-1
EP4334340A1 (en) * 2021-05-07 2024-03-13 The United States of America, as represented by the Secretary, Department of Health and Human Services T cell receptors recognizing c135y, r175h, or m237i mutation in p53
WO2023060195A1 (en) * 2021-10-08 2023-04-13 Baylor College Of Medicine Targeting common somatic mutations in breast cancer with neo-antigen specific adoptive t cell therapy
EP4423143A4 (en) * 2021-10-29 2025-10-01 Yafei Hou T CELL RECEPTOR RECOGNIZING R175H MUTATION IN P53 AND ITS APPLICATION
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
WO2024076692A1 (en) * 2022-10-05 2024-04-11 Icahn School Of Medicine At Mount Sinai Heterobifunctional compounds as p53 acetylators
WO2024163371A1 (en) * 2023-01-30 2024-08-08 Fred Hutchinson Cancer Center Binding proteins specific for mutant p53 and uses thereof
AU2024241888A1 (en) 2023-03-27 2025-10-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting y220c or r175h mutation in p53
WO2024220520A2 (en) * 2023-04-21 2024-10-24 Board Of Regents, The University Of Texas System T-cell receptors targeting her2 and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
PT3149031T (pt) 2014-05-29 2020-03-25 Us Health Receptores de células t anti-e7 do papilomavírus humano 16
EP3770168A1 (en) 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
IL273515B2 (en) * 2017-09-29 2026-03-01 Us Health T cell receptors that recognize mutated P53
JP7391015B2 (ja) * 2017-09-29 2023-12-04 アメリカ合衆国 P53がん特異的変異に対して抗原特異性を有するt細胞を単離する方法
CN107748893A (zh) * 2017-09-29 2018-03-02 阿里巴巴集团控股有限公司 提升车辆定损图像识别结果的方法、装置及服务器
EP4334340A1 (en) 2021-05-07 2024-03-13 The United States of America, as represented by the Secretary, Department of Health and Human Services T cell receptors recognizing c135y, r175h, or m237i mutation in p53
AU2024241888A1 (en) 2023-03-27 2025-10-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting y220c or r175h mutation in p53

Also Published As

Publication number Publication date
EP3990481A1 (en) 2022-05-04
US12479902B2 (en) 2025-11-25
MX2026003696A (es) 2026-06-01
WO2020264269A1 (en) 2020-12-30
KR20220047969A (ko) 2022-04-19
MX2021015877A (es) 2022-04-18
TWI908730B (zh) 2025-12-21
JP2025081413A (ja) 2025-05-27
TW202525841A (zh) 2025-07-01
US20220332785A1 (en) 2022-10-20
AU2020308004A1 (en) 2022-02-03
AU2020308004B2 (en) 2026-03-19
TW202108609A (zh) 2021-03-01
CN114341171A (zh) 2022-04-12
JP7635165B2 (ja) 2025-02-25
JP2022538148A (ja) 2022-08-31
CA3144070A1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
MX2021015877A (es) Receptores de celulas t que reconocen la mutacion r175h o y220c en p53.
MX2024005676A (es) Receptores de celulas t que reconocen p53 mutado.
EA202091335A1 (ru) Ограниченные hla класса i t-клеточные рецепторы против мутантного ras
MX2015003061A (es) Receptores de la celula t que reconocen mhc de mage-a3 de calse ii-restringida.
MX2024004610A (es) Receptores de celulas t restringidas a hla de clase ii contra ras mutado.
BR112022015897A2 (pt) Receptores de célula t restritos à classe i de hla contra ras com mutação de g12v
CY1125601T1 (el) Υποδοχεις anti-kras-g12d κυτταρων τ
MX2018003062A (es) Receptores de celula t que reconocen kras mutante restringido en hla-cw8.
EA202092044A1 (ru) Химерные рецепторы антигена против cd33 и их применения
BR112022015888A2 (pt) Receptores de células t restritos a hla classe i contra ras com mutação g12d
MX2017006865A (es) Receptores de células t de kras anti-mutado.
BR112014024282A2 (pt) anticorpos ligantes ao receptor b1 da bradicinina
MX2016015383A (es) Receptores de celulas t anti - papilomavirus 16 e7 humano.
BR112012005713A2 (pt) vacinas direcionadas a célula langerhans.
BR112022016661A2 (pt) Receptores de células t restritos ao hla classe ii contra ras com mutação g12v
BR112012009854B8 (pt) proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, método de confecção da referida proteína de ligação e uso da mesma
CY1116413T1 (el) Καινοφανη πληρως-ανθρωπινα μονοκλωνικα αντισωματα anti-vap-1
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
PH12013500204A1 (en) Polypeptides for treating and/or limiting influenza infection
BR112012018457A2 (pt) peptídeos melk modificados e vacinas contendo os mesmos
BR112023005296A2 (pt) Receptores de células t específicos de mage-a3 e uso dos mesmos
BR112023022367A2 (pt) Anticorpos anti-tigit e métodos de uso dos mesmos
BR112013013158B1 (pt) composições farmacêutica para uso no tratamento de câncer, métodos in vitro para induzir célula apresentadora de antígeno, bem como vetor, e uso
WO2021262829A3 (en) Hla class i-restricted t cell receptors against cd20
BR112014024230A8 (pt) Polipeptídeo, derivado do polipeptídeo, ácido nucleico, vetor, célula hospedeira, método de produção do polipeptídeo, composição farmacêutica, kit, método de inibição de atividade de notch, método de tratamento de uma doença, anticorpo isolado, método de o aumento da atividade de notch